Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 9/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011453 | 0.88 | HTR7 (0.37) | MAP3K5HTR7ADRA1DADRA1AADRA1B | |
| SCHEMBL3924760 | 0.85 | HRH4 (0.43) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL3927808 | 0.84 | NPC1 (0.36) | HTR7KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL3924707 | 0.83 | MKNK1 (0.45) | HTR7KDM4ECCNB2CCNE2ALDH1A1 | |
| SCHEMBL3924645 | 0.81 | CCNE2 (0.45) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL5948011 | 0.77 | CCNE1 (0.48) | CCNB2CCNE2CDK1CCNB1CCNA2 | |
| SCHEMBL3923592 | 0.77 | DPP4 (0.37) | KDM4EALDH1A1MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL3923646 | 0.76 | VCP (0.35) | CCNE2CYP3A4CYP2D6CCNA2CCNE1 | |
| SCHEMBL3933938 | 0.76 | GRIN2B (0.41) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL3922932 | 0.75 | KDR (0.39) | CDK1CCNA2CDK2CCNA1CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | claimed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | claimed |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | claimed |
| EP-2041118-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007114827-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247263-A1 | Substituted heterocyclic compounds and methods of use | MAPT, IAPP, MYLK2 | MAP3K5 1612/4885HTR7 3180/4885ADRA1D 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.